Tags

Type your tag names separated by a space and hit enter

Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Expert Rev Neurother. 2012 Feb; 12(2):119-31.ER

Abstract

Levodopa has been the mainstay of Parkinson's disease (PD) therapy for over 40 years, with its efficacy surpassing that of other antiparkinsonian medications. As such, most PD patients eventually require levodopa-based therapy during the course of the disease. However, despite its proven efficacy, long-term levodopa therapy is associated with motor complications, with wearing-off being the most prevalent. Wearing-off occurs, in part, as a result of the short half-life of levodopa, which leads to fluctuations in plasma levodopa levels. A pharmacokinetic profile characterized by a higher trough value of levodopa can be achieved by combining levodopa/carbidopa with entacapone, which inhibits the peripheral breakdown of levodopa, resulting in higher plasma levodopa levels. Here, we review the limitations of conventional levodopa and the clinical data for levodopa/carbidopa/entacapone in treating patients with wearing-off.

Authors+Show Affiliations

Department of Neurology, University of Dresden, Dresden, Germany. heinz.reichmann@mailbox.tu-dresden.deNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22288667

Citation

Reichmann, Heinz, and Murat Emre. "Optimizing Levodopa Therapy to Treat Wearing-off Symptoms in Parkinson's Disease: Focus On Levodopa/carbidopa/entacapone." Expert Review of Neurotherapeutics, vol. 12, no. 2, 2012, pp. 119-31.
Reichmann H, Emre M. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone. Expert Rev Neurother. 2012;12(2):119-31.
Reichmann, H., & Emre, M. (2012). Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone. Expert Review of Neurotherapeutics, 12(2), 119-31. https://doi.org/10.1586/ern.11.203
Reichmann H, Emre M. Optimizing Levodopa Therapy to Treat Wearing-off Symptoms in Parkinson's Disease: Focus On Levodopa/carbidopa/entacapone. Expert Rev Neurother. 2012;12(2):119-31. PubMed PMID: 22288667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone. AU - Reichmann,Heinz, AU - Emre,Murat, PY - 2012/2/1/entrez PY - 2012/2/1/pubmed PY - 2012/6/23/medline SP - 119 EP - 31 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 12 IS - 2 N2 - Levodopa has been the mainstay of Parkinson's disease (PD) therapy for over 40 years, with its efficacy surpassing that of other antiparkinsonian medications. As such, most PD patients eventually require levodopa-based therapy during the course of the disease. However, despite its proven efficacy, long-term levodopa therapy is associated with motor complications, with wearing-off being the most prevalent. Wearing-off occurs, in part, as a result of the short half-life of levodopa, which leads to fluctuations in plasma levodopa levels. A pharmacokinetic profile characterized by a higher trough value of levodopa can be achieved by combining levodopa/carbidopa with entacapone, which inhibits the peripheral breakdown of levodopa, resulting in higher plasma levodopa levels. Here, we review the limitations of conventional levodopa and the clinical data for levodopa/carbidopa/entacapone in treating patients with wearing-off. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/22288667/Optimizing_levodopa_therapy_to_treat_wearing_off_symptoms_in_Parkinson's_disease:_focus_on_levodopa/carbidopa/entacapone_ L2 - https://www.tandfonline.com/doi/full/10.1586/ern.11.203 DB - PRIME DP - Unbound Medicine ER -